Skip to Main Content

Paper Details

Response Rates to Anti-PD-1 Immunotherapy in Microsatellite-Stable Solid Tumors With 10 or More Mutations per Megabase.
JAMA Oncol
114
2021
Microsatellite-Stable Solid Tumors, Participants, Patients, TMB, Tumors, anti-programmed cell death 1, cancer, kidney cancers, malignant solid tumors, melanoma, melanomas, pancreatic cancer, patients, programmed cell death 1, programmed cell death ligand-1, solid tumors, tumor, tumors
Author NameAffiliation
Mark LeeMemorial Sloan Kettering Cancer Center
Michael F BergerMemorial Sloan Kettering Cancer Center
Michael F BergerMarie-Josee and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center
Timothy A ChanMemorial Sloan Kettering Cancer Center
Timothy A ChanLerner Research Institute, Cleveland Clinic
Timothy A ChanCenter for Immunotherapy and Precision Immuno-Oncology, Cleveland Clinic
Timothy A ChanMemorial Sloan Kettering Cancer Center
Timothy A ChanCenter for Immunotherapy and Precision Immuno-Oncology, Cleveland Clinic
Timothy A ChanLerner Research Institute, Cleveland Clinic
Luc G T MorrisMemorial Sloan Kettering Cancer Center
  • 1 - 10

Datasets

Release 1.2